BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
75.98
+1.03 (1.37%)
Nov 2, 2026, 11:55 AM EST - Market open
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $14.8 billion as of November 2, 2026. It is the 1,531st most valuable company in the world and the 589th biggest in the United States. Its market cap has increased by 22.61% in one year.
Market Cap
14.80B
Enterprise Value
16.64B
1-Year Change
22.61%
Global Rank
Country Rank
#589 United States
Category
ChartMarket Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $14.80B, an increase of 345.84%. That is a compound annual growth rate of 22.53%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 2, 2026 | 14.80B | 0.41% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Exelixis | 16.93B |
| Ascendis Pharma | 16.50B |
| Halozyme Therapeutics | 14.86B |
| Jazz Pharmaceuticals | 14.02B |
| Summit Therapeutics | 12.82B |
| Bio-Techne | 11.39B |
| BioMarin Pharmaceutical | 11.33B |
| Kymera Therapeutics | 10.81B |